. , (410012, , .

12
1
.
,
1
.
,
1
(410012,
, .
,
,
,
, 112) [email protected]
«
»,
,
., . 112)
.
2
(191119,
2
.
, .
[email protected]
» - http://www.famous-scientists.ru
,
,
-
,
.
,
.
,
,
-
.
,
,
-
,
[6].
-
,
0.07
– 0.5
.
.
,
85%
,
-
(
10
)
-
,
.
-
.
8-10
100
,
15
(
70%.
,
.
,
., 2005).
,
-
.
,
,
.
,
200-250
4-6 %
,
.
-
4, 2009
13
10-15
.
.
-
2.
,
,
,
[11].
-
,
,
,
.
,
,
.
,
,
85%
;
,
(NO),
(
-
,
:
,
-
.
,
3.
-
),
,
. [5].
,
,
,
.
,
[5, 6].
-
NO
,
.
4.
,
,
,
,
.
5.
-
,
,
–
1
-
.
«
-
»
,
-
–
.
.
,
-
,
,
(
[4,7,8].
-
(
),
:
(
,
1.
-
,
)
-
.
100
)
,
-
.
.
4, 2009
-
14
80
-
250-300 .
.
«
».
,
-
,
72
<0.001,
. 1)
<0.001,
. 2)
-
–
),
(
) [2,3],
(
)
,
-
«
»).
.
-
,
-
,
:
,
H.Selye.
.
,
-
.
1
[9].
2
.
,
1
-
,
-
,
.
36
.
-
,
-
(
-
,
–
)
,
,
,
,
,
.
.
-
-
,
-
:
+ NAD+
.
+ NADH+ +
+
-
.
[8].
,
60
( <0.01,
.1)
.
,
,
NAD+
-
+
-
[8].
-
<0.01,
,
.2)
60
,
(
.
(
,
.3)
. 6)
,
,
-
.
4, 2009
-
15
NAD+
72
NADH++.
NADH++
,
( <0.001,
. 3).
,
,
<0.001,
,
. 7)
,
-
,
[8].
.
-
-
,
,
,
,
-
,
.
.
,
-
.
.
,
60
-
,
( <0.01,
. 4)
.
72
,
-
,
( <0.001,
,
[8].
. 4).
.
,
2,
.
-
,
,
–
65-90%.
.
,
–
[8].
,
,
-
[8].
,
60
-
,
,
.
72
,
,
-
.
,
–
.
,
,
,
-
.
,
-
-
-
.
.
,
,
,
-
2
4, 2009
16
.
,
,
-
4.
,
,
[8].
-
<0.001,
.5)
. 5),
–
-
,
.
( <0.001,
60
-
,
.
,
72
.
–
.
5.
-
,
,
)
-
,
.
( <0.001,
,
,
,
,
. 6)
-
.
6.
.
:
,
:
1.
,
-
–
,
-
-
.
.
2.
-
,
,
2, 6
.
3.
-
:
-
:
,
–
,
«
[1,10].
.
4, 2009
.
»,
-
17
3
2,5
2
1,5
1
0,5
0
,
60
,
.
60
,
72
,
72
.
. 1.
.
:
60
–
.
–
72
,
.
.
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0
,
60
,
60
,
72
. .2.
2.
72
.
.
:
60
,
–
.
72
–
.
.
4, 2009
,
18
1,4
1,2
1
0,8
0,6
0,4
0,2
0
,
60
,
60
.
,
72
.
,
. 3.
72
.
.
:
60
–
.
–
72
,
.
.
3,5
3
2,5
2
1,5
1
0,5
0
,
60
.
,
60
,
72
,
72
.
. 4.
.
:
60
–
.
72
–
.
.
4, 2009
,
19
70
60
50
40
30
20
10
0
,
60
,
60
,
72
,
72
. 5.
.
:
60
–
.
–
72
,
.
.
4
3,5
3
2,5
2
1,5
1
0,5
0
,
60
,
60
,
72
. 6.
,
72
.
60
:
.
–
72
–
.
.
4, 2009
,
20
5
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0
,
60
,
.
60
72
,
.
72
.
. 7.
.
60
:
.
–
–
72
,
.
.
:
1.
.
.,
.,
.,
.,
-
.
,
.
. – 1996. 7.
-
//
-
4 – . 3-6.
.
/
.
//
. – 2002. 65, 1. . 27-29.
2.
.,
,
, 1982. – .224-226
.,
.,
.
,
, 1982. –
3.
. 210-212.
4.
,
.
-
.
.,
.
.
2. /
.
.–
.–
.:
, 2000. – 687 . – . 363-364.
5.
.
.
/ .
.
//
:
.
. .–
:
, 1997. – . 266-269.
6.
.,
.
.
/
. 6. - .:
. 92-114.
8.
:
.
., 2002. – 464 .:
//
:
. –
. – .:
». 2005. – 480 . –
«
. 140-151.
9.
.,
.,
. 33-35.
10.
.,
. //
. – 2006. -
3.
.,
.,
.
. //
. –
2003. –
11.
3,
2. . 90-97.
.
/
/-
.
.: «
. 336-350.
4, 2009
//
». 1982. –
21
THE COMPARATIVE EVALUATION OF ENERGY SUPPLY OF MYOCARDIUM
IN NORM AT EXPERIMENTAL PERACUTE ISCHEMIA
M.N. Bizenkova, N.P. Chesnokova, M.G. Romantsov
Saratov State Medical University, Saratov
Scientific-technological pharmaceutical company “Polysun”, Saint-Petersburg
The comparative evaluation of energy supply of myocardium in norm of white rats experimental peracute ischemia allowed to discover the progressive decreasing of adenosine triphosphate content in myocardium, phosphocreatine content, succinate dehydrogenase activity, lactate dehydrogenase and aspartate aminotransferase homogenates of myocardium. In myocardium ischemia dynamics the decreasing of the activity of blood serum aspartate aminotransferase took place, in the meantime the activity of blood serum lactate dehydrogenase underwent
phase changes. Metabolic shifts in myocardium at ischemia testifies the advisability of use in
complex therapy of the mentioned pathology not only high-energy compounds, but antihypoxants, providing the activation of Krebs cycle and high-energy effects prolongation, as well.
4, 2009